These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1351537)

  • 21. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.
    Rilke F; Colnaghi MI; Cascinelli N; Andreola S; Baldini MT; Bufalino R; Della Porta G; Ménard S; Pierotti MA; Testori A
    Int J Cancer; 1991 Aug; 49(1):44-9. PubMed ID: 1678734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
    Allred DC; Clark GM; Tandon AK; Molina R; Tormey DC; Osborne CK; Gilchrist KW; Mansour EG; Abeloff M; Eudey L
    J Clin Oncol; 1992 Apr; 10(4):599-605. PubMed ID: 1548522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl-2 protein expression and long-term survival in breast cancer.
    Joensuu H; Pylkkänen L; Toikkanen S
    Am J Pathol; 1994 Nov; 145(5):1191-8. PubMed ID: 7977649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
    Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
    Zhang GH; Yang WT; Zhou XY; Zeng Y; Lu HF; Shi DR
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):155-60. PubMed ID: 17425844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-erbB-2 overexpression and survival in early onset breast cancer.
    Agrup M; Stål O; Olsen K; Wingren S
    Breast Cancer Res Treat; 2000 Sep; 63(1):23-9. PubMed ID: 11079156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pepsinogen C is a new prognostic marker in primary breast cancer.
    Vizoso F; Sánchez LM; Díez-Itza I; Merino AM; López-Otín C
    J Clin Oncol; 1995 Jan; 13(1):54-61. PubMed ID: 7799043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].
    Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1181-5. PubMed ID: 1675844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
    Lovekin C; Ellis IO; Locker A; Robertson JF; Bell J; Nicholson R; Gullick WJ; Elston CW; Blamey RW
    Br J Cancer; 1991 Mar; 63(3):439-43. PubMed ID: 1672254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.
    Harris LN; Liotcheva V; Broadwater G; Ramirez MJ; Maimonis P; Anderson S; Everett T; Harpole D; Moore MB; Berry DA; Rizzeri D; Vredenburgh JJ; Bentley RC
    J Clin Oncol; 2001 Mar; 19(6):1698-706. PubMed ID: 11250999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study.
    Haffty BG; Brown F; Carter D; Flynn S
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):751-7. PubMed ID: 8690641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.
    Pupa SM; Bufalino R; Invernizzi AM; Andreola S; Rilke F; Lombardi L; Colnaghi MI; Ménard S
    J Clin Oncol; 1996 Jan; 14(1):85-94. PubMed ID: 8558226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.